The experience of uterine fibroids treatment with selective progesterone-receptor modulator

Adamyan L.V.; Sonova M.M.; Shamugia N.M.

doi:https://doi.org/

Adamyan L.V.

Department of Reproductive Medicine and Surgery, Faculty of Postgraduate Professional Education, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

SPIN RSCI: 9836-2713
Scopus AuthorID: 7006372422
ResearcherID: Q-1722-2018
ORCID: 0000-0002-3253-4512

Sonova M.M.

Kafedra reproduktivnoĭ meditsiny i khirurgii fakul'teta poslediplomnogo obrazovaniia Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Shamugia N.M.

The experience of uterine fibroids treatment with selective progesterone-receptor modulator

Authors:

Adamyan L.V., Sonova M.M., Shamugia N.M.

More about the authors

Journal: Russian Journal of Human Reproduction. 2014;(4): 34‑38

Read: 6804 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Adamyan LV, Sonova MM, Shamugia NM. The experience of uterine fibroids treatment with selective progesterone-receptor modulator. Russian Journal of Human Reproduction. 2014;(4):34‑38. (In Russ.)

Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Atypical location of uterine fibroids: a view of an unusual clinical case through the lens of diagnostics and surgery. Russian Journal of Human Reproduction. 2026;(1):86-91

Use of gonadotropic releasing hormone agonists in hyperplastic syndrome in gynecology. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):51-58

Morpho-functional features of the endometrium in uterine leiomyoma before and after embolization of the uterine arteries. Russian Journal of Archive of Pathology. 2025;(4):13-23

Leiomyoma in the dermatovenerologist’s practice. Russian Journal of Clinical Dermatology and Venereology. 2025;(6):760-764

Leiomyosarcoma of the uterine body in a patient of early reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2026;(1):88-93

Abstract:

The experience of Ulipristal acetate as selective progesterone-receptor modulator which inhibits the proliferation and induces apoptosis of leiomyoma cells in vitro is presented. It modulates the expression of vascular endothelial growth factors and hormone receptors and modulates the extracellular matrix breakdown in leiomyoma cells but not in myometrial cells. Uterine bleeding was rapidly controlled by ulipristal acetate. About half of patients received of ulipristal acetate 5 mg/day became amenorrhoeic within the first 10 days of treatment. Furthermore, uterine bleeding was controlled significantly more rapidly with Ulipristal acetate compared with leuprolide acetate.

Keywords:

leiomyoma

Ulipristal acetate

agonists GnRH